Skip to main content
. 2011 Sep 29;7(3):128–136. doi: 10.3988/jcn.2011.7.3.128

Table 2.

Differences of demographic and clinical variables according to the completion of the study

graphic file with name jcn-7-128-i002.jpg

*Discontinuation of LEV within 4 weeks due to serious adverse events, Differences of variables between groups were analyzed by the independent t-test or Fisher's exact test.

LEV: levetiracetam, TLE: temporal lobe epilepsy.

HHS Vulnerability Disclosure